PHARMA MAR, S.A. Patent applications |
Patent application number | Title | Published |
20130266666 | Combination Therapy with an Antitumor Alkaloid - The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer. | 10-10-2013 |
20130066067 | Synthetic Process for the Manufacture of Ecteinascidin Compounds - This invention relates to compounds of formula II: wherein R | 03-14-2013 |
20130040921 | ANTICANCER STEROIDAL LACTONES UNSATURATED IN POSITION 7 (8) - A compound of general formula (I), wherein R | 02-14-2013 |
20120107417 | Effective Antitumor Treatments - ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug. | 05-03-2012 |
20120041063 | ANTITUMORAL COMPOUNDS -
A compound of general formula (I)
| 02-16-2012 |
20110237520 | Anticancer Compounds - Compounds of general formula I: | 09-29-2011 |
20110207674 | ANTITUMORAL COMPOUNDS -
Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof
| 08-25-2011 |
20110105409 | Anticancer Compounds - Anticancer compounds of general formula I: | 05-05-2011 |
20110076343 | Multiple Myeloma Treatments - Methods for treating cancer by using compound PM00104, in particular, for treating multiple myeloma are provided. | 03-31-2011 |
20110070232 | Combination Therapy with an Antitumor Alkaloid - The present invention relates to combinations of PM00104 with other anticancer drugs, and the use of these combinations in the treatment of cancer. | 03-24-2011 |
20110034549 | Antitumoral Compounds - A compound of general formula (I) | 02-10-2011 |
20110015135 | Antitumoral Treatments - The present invention relates to combinations of PM02734 with another anticancer drug selected from Cisplatin, Gemcitabine, Paclitaxel, Oxaliplatin, 5-Fluorouracil, Trabectedin, Rapamycin, and Sunitinib, and the use of these combinations in the treatment of cancer. | 01-20-2011 |
20100323021 | ANTITUMORAL TREATMENTS - The present invention relates to colloidal metal nanoparticles conjugated with Kahalalide F, or an analogue thereof, and their use in the treatment of cancer. The invention also relates to a method for increasing the antitumoral activity of Kahalalide F, or an analogue thereof, which comprises conjugating the Kahalalide F, on an analogue thereof, with a colloidal metal nanoparticle. | 12-23-2010 |
20100292163 | Antitumoral Compounds - Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof | 11-18-2010 |
20100280108 | Antitumoral Compounds - A compound of general formula (I) | 11-04-2010 |
20100267732 | Prognostic Molecular Markers for ET-743 Treatment - The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein and/or having a “wild type” genotype for Asp1104His SNP of XPG gene. | 10-21-2010 |
20100240595 | Improved Antitumoral Treatments - The present invention relates to combinations of Aplidine with Gemcitabine, and the use of these combinations in the treatment of cancer. | 09-23-2010 |
20100226919 | Antitumoral Treatments - The present invention relates to combinations of PM02734 with EGFR tyrosine kinase inhibitors, and the use of these combinations in the treatment of cancer. | 09-09-2010 |
20100216817 | Antitumoral Tetrahydro-Pyrimidines - Antitumoral compounds of the formula (I) wherein X is O, S, or NRa, obtained from a maze coral of the family Meandrinidae, genus | 08-26-2010 |
20100048690 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS - Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus | 02-25-2010 |
20100048596 | Indole Derivatives as Antitumoral Compounds - Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R | 02-25-2010 |
20100041594 | Use of Aplidine for the Treatment of Pancreatic Cancer - Aplidine is active against cancer of the pancreas, including metastatic pancreatic cancer. | 02-18-2010 |
20100009906 | Anticancer Treatments - A method of treating the human body for cancer comprises administering an effective therapeutic amount of docetaxel in combination with an effective therapeutic amount of ET-743. | 01-14-2010 |
20090324744 | Effective Antitumor Treatments - ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug. | 12-31-2009 |
20090298752 | APLIDINE TREATMENT OF CANCERS - Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumors, and various dosing regimes are given. Tumor reduction has been observed in several tumor types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumor activity. | 12-03-2009 |
20090246168 | ANTITUMORAL TREATMENTS - The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma. | 10-01-2009 |
20090197901 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS - Variolin derivatives of formula (5) are provided, wherein the substituent groups defined by X | 08-06-2009 |
20090186938 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS - Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus | 07-23-2009 |
20090163507 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS - Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided. | 06-25-2009 |
20090130675 | Genes Involved in the Biosynthesis of Thiocoraline and Heterologous Production of Same - The invention relates to genes involved in the biosynthesis of thiocoraline and to the heterologous production of same. According to the invention, the cluster of genes responsible for the biosynthesis of thiocoraline was identified and cloned. Said cluster of genes can be used in the heterologous production of thiocoraline which has an antitumor and antibacterial activity. | 05-21-2009 |
20090124647 | Indole Derivatives as Antitumoral Compounds - Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R | 05-14-2009 |
20090076016 | FORMULATIONS COMPRISING JORUMYCIN-, RENIERAMYCIN-, SAFRACIN- OR SAFRAMYCIN-RELATED COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES - Jorumycin, renieramycin, safracin and saframycin related compounds formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided. | 03-19-2009 |
20090030068 | Antitumour Compounds - The invention relates to novel antitumor compounds of general formula | 01-29-2009 |
20080318849 | Kahalalide F and Related Compounds - A process is provided for preparing kahalalide F and which leads to other kahalalide mimic compounds having useful biological activity. | 12-25-2008 |
20080234363 | Antitumoral Compounds - Compounds of general formula (I), wherein R | 09-25-2008 |